PharmaJet Received Multi-Year, Multi-Million Dollar Award to Support Next-Generation Needle-free Delivery Devices
By: Colorado BioScience Association Date: 03/18/2020
Technology being used to progress nucleic acid vaccines
GOLDEN, Colo. — March 17, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that it received a $9.6 million dollar contract award from the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency (DTRA). DTRA, through the Medical CBRN Defense Consortium (MCDC), is funding the use of needle-free technology to further progress promising nucleic acid vaccines, while also funding the development of PharmaJet’s next generation needle-free devices. The initial studies underway are focused on delivery of Venezuelan Equine Encephalitis Virus (VEEV) DNA Vaccines developed by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) using the PharmaJet systems.
This award is in response to the need for devices that can effectively deliver nucleic acid-based vaccines and are also compatible with military operations or a field environment. Traditional electroporation devices posed a concern to military operations because of their bulky size, need for power supplies, patient discomfort and device sterilization issues. The PharmaJet Needle-free Injection Systems are easy-to-use and optimized for field use. Multiple studies delivering DNA vaccines with PharmaJet systems have shown immunogenicity levels higher than with needle-syringe and comparable to electroporation.(1) The next generation needle-free devices will further enable the rapid development of nucleic acid vaccines and therapeutics.
Chris Cappello, President and Chief Executive Officer, PharmaJet Inc. said, “we are excited to be collaborating with the U.S. Government to progress their vaccine development and next generation needle-free devices, which could include variable dose devices for additional pathogens. Our systems are already being used extensively in the field due to their ease-of-use, minimal training requirements and fast administration time.”
For more information visit www.pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
(1) Gaudinski, MR. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet. 2018. Feb, 391(10120), 552-562.
PharmaJet’s mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. The innovative Stratis® Needle-free Injection System has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® Needle-free Injection System has CE Mark and WHO PQS certification for intradermal injections.
# # #